Squarepoint
BCAB icon

Squarepoint’s BioAtla BCAB Stock Holding History

Squarepoint’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,205
Closed -$90.3K – 4488
2025
Q1 		$90.3K Buy
5,205
+4,270
+457% +$91.3K ﹤0.01% 4244
2024
Q4 		$27.6K Buy
+935
New +$78.5K ﹤0.01% 4913
2024
Q3 		– Sell
-1,412
Closed -$96.7K – 4113
2024
Q2 		$96.7K Buy
+1,412
New +$168K ﹤0.01% 3808
2023
Q2 		– Sell
-384
Closed -$51.4K – 3563
2023
Q1 		$51.4K Buy
384
+85
+28% +$15.3K ﹤0.01% 3053
2022
Q4 		$123K Buy
+299
New +$124K ﹤0.01% 2930
2022
Q3 		– Sell
-698
Closed -$99K – 2992
2022
Q2 		$99K Sell
698
-1,404
-67% -$223K ﹤0.01% 2621
2022
Q1 		$525K Buy
2,102
+1,765
+524% +$738K ﹤0.01% 1975
2021
Q4 		$331K Buy
+337
New +$431K ﹤0.01% 2392
2021
Q3 		– Sell
-158
Closed -$336K – 2912
2021
Q2 		$336K Buy
+158
New +$357K ﹤0.01% 2444

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Squarepoint's BCAB Position: Q2 2025 in Review

Squarepoint sold out of BioAtla (BCAB) in Q2 2025, closing a stake of 5,205 shares — an estimated $90.3K sold.

Squarepoint first reported a position in BCAB in Q2 2021 and held it in 9 quarters. The position peaked at $525K in Q1 2022. 39 funds tracked by Wall St. Rank hold BCAB as of Q2 2025.

  • Squarepoint reported no remaining BioAtla position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 5,205 BioAtla shares in Q2 2025, an estimated $90.3K.
  • Squarepoint first reported a position in BioAtla in Q2 2021 and held it in 9 quarters.
  • Squarepoint's BioAtla position peaked at $525K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held BioAtla as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.